Physician profile
Kaylee Timlin
NPI 1326611708
$1,443.21
in general payments reported to CMS, 2019-2025
11 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2022: $193 · 2023: $382 · 2024: $329 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.47 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $319.42 | 2022-2024 | |
| Legend Biotech USA INC. | $279.10 | 2024-2025 | Carvykti |
| Beone Medicines USA, INC. | $277.88 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $245.60 | 2021-2025 | Carvykti, Darzalex, Tecvayli |
| Astellas Pharma Global Development | $117.07 | 2023 | Xospata |
| Abbvie INC. | $84.09 | 2022-2023 | |
| Astellas Pharma US INC | $31.25 | 2023 | Xospata |
| Jazz Pharmaceuticals INC. | $29.50 | 2023 | |
| Karyopharm Therapeutics INC. | $26.25 | 2022 | |
| Incyte Corporation | $19.11 | 2023 | Jakafi |
| Genzyme Corporation | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Timlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.